SmartLinker™
Precision linker technology for antibody–payload conjugation
A linker and conjugation platform designed to connect antibodies with nanoparticles and other payloads for therapeutic and diagnostic applications.
Designing Better
Biotherapeutics
Founded in 2018 at the University of Strathclyde, SiMologics is developing platform technologies to engineer next-generation antibody-based therapeutics with improved precision, performance, and clinical potential.
Our Technology Platforms
Why Better Biotherapeutics Matter
Antibody development is often expensive, slow, and resource-intensive. SiMologics uses digital technologies to help design and evaluate better therapeutic and diagnostic antibodies earlier in development.
Faster Development
Use AI, machine learning, and molecular dynamics to accelerate antibody design and analysis.
Lower Development Risk
Identify stronger candidates earlier and reduce unnecessary experimental iterations.
More Sustainable R&D
Reduce laboratory waste, material consumption, and the environmental footprint of antibody development.
Better Patient Impact
Support faster, more cost-effective progression of improved antibodies toward patients.
Applications
Targeted cancer biotherapeutics
Antibody–nanoparticle conjugates
Antibody–payload conjugation
AI-enabled antibody discovery and optimisation
Work With SiMologics
We welcome collaborations with academic groups, biotech companies, translational researchers, CROs, funders, investors and innovation partners.